Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Astellas to pay Sutro $90 million for ADCs for cold tumors

by Gina Vitale
June 30, 2022 | A version of this story appeared in Volume 100, Issue 24

 

Astellas Pharma and the cancer therapy company Sutro Biopharma have formed a partnership to advance immunostimulatory antibody-drug conjugates (ADCs). They aim to use the ADCs to treat cold tumors, which are tumors that are unlikely to bring about a strong immune response. Sutro will get $90 million to develop ADCs for three biological targets and up to $422.5 million in milestones for each. Astellas will be responsible for clinical development.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.